2024-10-09 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis Report

**Company Overview:** Johnson & Johnson is a multinational pharmaceutical, medical devices, and consumer packaged goods company.

**Performance Analysis:**

**1.  Return Rate Comparison:**

* **JNJ Cumulative Return:** 33.77%
* **S&P 500 (VOO) Cumulative Return:** 133.14%
* **Return Difference:** -99.37%
* **Relative Divergence:** 5.34%

**Interpretation:** JNJ has significantly underperformed the S&P 500 over the analyzed period. It's currently at the 5.34% percentile of its historical performance relative to the S&P 500. 

**2.  Recent Price Movement:**

* **Closing Price:** 160.29
* **5-Day Moving Average:** 161.2
* **20-Day Moving Average:** 163.72
* **60-Day Moving Average:** 161.09

**Interpretation:**  The stock is currently trading below its 5, 20, and 60-day moving averages, indicating a possible downtrend.

**3.  Technical Indicators:**

* **RSI:** 19.93
* **PPO:** -0.38
* **Delta Previous Relative Divergence:** -13.51 (Short-term downtrend)
* **Expected Return:** 0.0% (Maximum 5-year expected return over S&P 500, VOO)

**Interpretation:**  Both RSI and PPO indicators suggest that JNJ is oversold.  The negative Delta Previous Relative Divergence confirms the short-term downtrend.  However, the Expected Return is currently at 0%, suggesting limited potential for outperforming the market in the next 5 years.

**4.  Recent Earnings and Outlook:**

| Date         | EPS   | Revenue       |
|--------------|-------|----------------|
| 2024-07-25  | 1.95  | 22.45 B$       |
| 2024-05-01  | 1.35  | 21.38 B$       |
| 2024-02-16  | 1.68  | 21.39 B$       |
| 2023-10-27  | 10.32 | 21.35 B$       |
| 2024-02-16  | 10.32 | 21.35 B$       |

**Interpretation:** While the most recent earnings report (2024-07-25) showed an EPS of 1.95, surpassing analyst expectations, the overall trend suggests a decline in revenue and EPS compared to the previous quarters.  This needs further examination to understand the reasons behind this decline and its impact on future earnings.

**5.  News and Recent Issues:**

* **Recent Market Outlook:**  Market sentiment towards JNJ has been mixed in recent months. Some analysts highlight its strong brand recognition and diversified business model as strengths, while others express concerns over its recent performance and the potential impact of legal issues and regulatory scrutiny on its pharmaceuticals division.
* **Analyst Opinions:** Analyst ratings for JNJ are generally "Hold" or "Buy", with some analysts suggesting a potential undervaluation.
* **Performance Highlights:**  JNJ has recently faced some challenges, including legal battles related to its talcum powder products and regulatory hurdles for its pharmaceutical division. However, the company is still considered a leader in its respective industries and continues to invest in research and development.

**6.  Overall Analysis:**

JNJ has underperformed the S&P 500 in recent years and is currently in a downtrend. Although it has shown a recent earnings beat, the overall trend points to a decline in revenue and EPS. Despite its strong brand and diversified business model, JNJ faces legal and regulatory challenges that impact its performance. While some analysts believe it is undervalued, the potential for future outperformance remains uncertain, especially with the expected return being at 0%. 

**7.  Recommendation:**

Based on the current analysis, JNJ might not be an ideal investment for investors seeking strong returns. It is recommended to monitor its performance closely, especially regarding future earnings reports and regulatory developments. Investors should weigh the risks associated with its legal and regulatory challenges against its potential for future growth.

**Disclaimer:** This analysis is based on publicly available information and should not be considered financial advice. Please consult with a qualified financial professional before making any investment decisions. 
